Table 1.

Anti-IL-23 monoclonal antibodies currently approved for the management of psoriasis.

	Guselkumaba	Tildrakizumabb	Risankizumabc
Antibody	Human monoclonal IgG1λ	Humanised monoclonal IgG1κ	Humanised monoclonal IgG1
Mechanism of action	Binding to the p19 subunit of IL-23 receptor	Binding to the p19 subunit of IL-23 receptor	Binding to the p19 subunit of IL-23 receptor
Dose and frequency of administration	100 mg s.c. at Weeks 0, 4, then every 8 weeks	100 mg s.c. at Weeks 0, 4, then every 12 weeks	150 mg s.c. at weeks 0,4, then every 12 weeks
Major side effects	Injections site reactions, upper respiratory infections, nasopharyngitis	Injections site reactions, upper respiratory infections, nasopharyngitis, headache, arthralgia	Viral upper respiratory tract infection, upper respiratory tract infection, urinary tract infection, influenza and headache

S.c., subcutaneous.

^aData from VOYAGE 1 and VOYAGE 2 trials.

^bData from reSURFACE1 and reSURFACE2 trials.

^cData from UltIMMa-1 and UltIMMa-2 trials.